Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2

Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2

Abstract Continued emergence of SARS-CoV-2 variants of concern that are capable of escaping vaccine-induced immunity highlights the urgency of developing new COVID-19 therapeutics. An essential mechanism for SARS-CoV-2 infection begins with the viral spike protein binding to the human ACE2. Conseque...

Full description

Bibliographic Details
Main Authors:	Zhenzhen Wang, Shiqi Hu, Kristen D. Popowski, Shuo Liu, Dashuai Zhu, Xuan Mei, Junlang Li, Yilan Hu, Phuong-Uyen C. Dinh, Xiaojie Wang, Ke Cheng
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-03-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-024-45628-x

Similar Items

Exosome therapeutics for COVID‐19 and respiratory viruses
by: Kristen D. Popowski, et al.
Published: (2021-06-01)

Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis
by: Phuong-Uyen C. Dinh, et al.
Published: (2020-02-01)

Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019
by: Halle Lutz, et al.
Published: (2021-03-01)

Bispecific Antibody Inhalation Therapy for Redirecting Stem Cells from the Lungs to Repair Heart Injury
by: Mengrui Liu, et al.
Published: (2021-01-01)

NSP6 inhibits the production of ACE2-containing exosomes to promote SARS-CoV-2 infectivity
by: Xi Lv, et al.
Published: (2024-03-01)

All Roads Lead to Rome (the Heart): Cell Retention and Outcomes From Various Delivery Routes of Cell Therapy Products to the Heart
by: Junlang Li, et al.
Published: (2021-04-01)

Combination therapy using inhalable GapmeR and recombinant ACE2 for COVID-19
by: Verma, Navin Kumar, et al.
Published: (2020)

Combination Therapy Using Inhalable GapmeR and Recombinant ACE2 for COVID-19
by: Navin Kumar Verma, et al.
Published: (2020-08-01)

Cells and cell derivatives as drug carriers for targeted delivery
by: Halle Lutz, et al.
Published: (2019-09-01)

Up-regulation of ACE2, the SARS-CoV-2 receptor, in asthmatics on maintenance inhaled corticosteroids
by: Sarah L. O’Beirne, et al.
Published: (2021-07-01)

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo
by: Zhaoyong Zhang, et al.
Published: (2021-08-01)

Exosomes-based particles as inhalable COVID-19 vaccines
by: Lu Fan, et al.
Published: (2023-12-01)

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2
by: Lianghui Zhang, et al.
Published: (2022-11-01)

An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants
by: Juan Liu, et al.
Published: (2023-08-01)

Inhalation of ACE2 as a therapeutic target on sex-bias differences in SARS-CoV-2 infection and variant of concern
by: Yu Onodera, et al.
Published: (2023-08-01)

Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants
by: Qi Li, et al.
Published: (2022-09-01)

The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry
by: Junsong Zhang, et al.
Published: (2021-05-01)

Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled recombinant human ACE2
by: Martin Bauer, et al.
Published: (2024-02-01)

Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling.
by: Nicola E Clarke, et al.
Published: (2012-01-01)

Nanoparticles functionalized with stem cell secretome and CXCR4-overexpressing endothelial membrane for targeted osteoporosis therapy
by: Chi Zhang, et al.
Published: (2022-01-01)

High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients
by: Chao Liu, et al.
Published: (2021-01-01)

In silico study of intrinsic dynamics of full-length apo-ACE2 and RBD-ACE2 complex
by: Qing Liu, et al.
Published: (2021-01-01)

ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study
by: Dipender Gill, et al.
Published: (2020-11-01)

Inhalation of Immuno-Therapeutics/-Prophylactics to Fight Respiratory Tract Infections: An Appropriate Drug at the Right Place!
by: Thomas Sécher, et al.
Published: (2019-11-01)

ACE2 Receptor and Its Isoform Short-ACE2 Are Expressed on Human Spermatozoa
by: Marina Ramal-Sanchez, et al.
Published: (2022-03-01)

Thymosin-α1 binds with ACE and downregulates the expression of ACE2 in human respiratory epithelia
by: Yu-Hang Zhang, et al.
Published: (2022-02-01)

ACE2 Shedding and the Role in COVID-19
by: Jieqiong Wang, et al.
Published: (2022-01-01)

Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies
by: Yifan Wang, et al.
Published: (2022-02-01)

Physical Activity and Inhibition of ACE Additively Modulate ACE/ACE-2 Balance in Heart Failure in Mice
by: Urszula Tyrankiewicz, et al.
Published: (2021-06-01)

Terminal Antennas in ACE2
by: M. Martinez-Vazquez, et al.
Published: (2008-06-01)

ACE and ACE2: insights from Drosophila and implications for COVID-19
by: Paul Herrera, et al.
Published: (2021-12-01)

ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs
by: Ivan T. Lee, et al.
Published: (2020-10-01)

Long Chain N3-PUFA Decreases ACE2 Protein Levels and Prevents SARS-CoV-2 Cell Entry
by: Shiqi Huang, et al.
Published: (2022-11-01)

Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2
by: Ming-Feng He, et al.
Published: (2022-10-01)

Prophylactic penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients: study protocol of a randomized controlled trial
by: Ting Yan, et al.
Published: (2017-11-01)

Engineered soluble ACE2 receptor: Responding to change with change
by: Guangyao Li, et al.
Published: (2023-01-01)

Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
by: Jiwan Ge, et al.
Published: (2021-01-01)

Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung cancer
by: Wei Zheng, et al.
Published: (2023-06-01)

The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19
by: Mira Bosso, et al.
Published: (2020-09-01)

Antcins from <i>Antrodia cinnamomea</i> and <i>Antrodia salmonea</i> Inhibit Angiotensin-Converting Enzyme 2 (ACE2) in Epithelial Cells: Can Be Potential Candidates for the Development of SARS-CoV-2 Prophylactic Agents
by: K. J. Senthil Kumar, et al.
Published: (2021-08-01)